Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
L Aprakast Injection
Manufacturer/Marketed By : APRAZER HEALTHCARE PVT LTD
$19.09 $12.22
L Aprakast Injection is a specialised anti-cancer formulation that contains the active constituent L Aprakast Injection, a crucial enzyme used in the treatment of certain hematologic malignancies. Classified under the...
Collapsible text is perfect for longer content like paragraphs and descriptions. It's a great way to give people more information while keeping your layout clean. Link your text to anything, including an external website or a different page. You can set your text box to expand and collapse when people click, so they can read more or less info.
L-ASPARAGINASE
Active Pharmaceutical Ingredient
L Aprakast Injection
US$ 19,09
US$ 12,22
L Aprakast Injection is a specialised anti-cancer formulation that contains the active constituent L Aprakast Injection, a crucial enzyme used in the treatment of certain hematologic malignancies. Classified under the therapeutic category of antineoplastic and immunomodulating agents, this product plays a vital role in the management of acute lymphoblastic leukaemia (ALL), particularly in pediatric and adolescent patients. By depleting the amino acid asparagine, which is essential for the survival and proliferation of leukemic cells, it effectively inhibits cancer cell growth and promotes remission when used as part of a combination chemotherapy regimen. This treatment must be administered under the strict supervision of an experienced oncologist due to its potential for serious side effects and hypersensitivity reactions. Prior to use, patients should be screened for pancreatic function, liver enzyme levels, and any history of hypersensitivity to proteins of bacterial origin. L Aprakast Injection.NPP is contraindicated in individuals with a known hypersensitivity to L Aprakast Injection.NPP, those with a history of severe pancreatitis, or those with significant hepatic dysfunction. Careful monitoring is recommended throughout the course of therapy to manage potential complications such as coagulopathy, pancreatitis, and hepatic toxicity. Always consult with a healthcare professional to ensure the safe and appropriate use of this medication.
Active Pharmaceutical Ingredient
Uses
• Treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapy protocol.
• Suitable for both pediatric and adult patients diagnosed with ALL.
• Being part of a group of medicines used during early and ongoing treatment stages.
• Helping patients who may be allergic to other types of asparaginase made from E. coli (depending on the formulation).
Benefits
This medicine works by targeting cancer cells that need a specific protein called asparagine to grow and survive. Normal cells in the body can make their own asparagine, but certain cancer cells, like those found in acute lymphoblastic leukaemia (ALL), cannot. They rely on getting it from the bloodstream. The treatment lowers the level of asparagine in the blood, which starves the cancer cells and helps stop them from growing or spreading.
Side Effects
Common Side Effects:
Most Common Side Effects
• Severe allergic reactions (rash, swelling, difficulty breathing)
• Inflammation of the pancreas (pancreatitis) – signs include severe abdominal pain
• Blood clotting issues (easy bruising, unusual bleeding)
• Liver problems (yellowing of skin or eyes, dark urine)
• Changes in mental status such as confusion or drowsiness
• Fever or signs of infection
Common Side Effects
• Nausea or vomiting
• Loss of appetite
• Fatigue or weakness
• Mild stomach pain
• Joint or muscle pain
• Temporary changes in blood sugar levels
How To Use
L Aprakast Injection is given by a healthcare professional in a hospital or clinic setting. It is not taken by mouth and should never be self-administered. The recommended dose varies based on body weight, age, and treatment protocol. It is usually given into a muscle (intramuscular) or vein (intravenous). Food intake does not affect this treatment, as it is not taken orally. Always follow your doctor’s dosing schedule and never miss an appointment for administration.
Safety Advice
• Breast Feeding: Do not breastfeed while receiving this medication. It is unknown whether the drug passes into breast milk, but it may pose risks to a nursing infant.
• Alcohol: Alcohol consumption should be avoided or limited, as it can increase the risk of liver damage and interfere with treatment.
• Liver: Use with caution in patients with liver disorders. Liver function should be monitored regularly during treatment.
• Lungs: In rare cases, respiratory complications may occur. Patients with pre-existing lung conditions should be closely monitored.
• Driving: This medicine may cause dizziness, confusion, or fatigue. Avoid driving or operating heavy machinery until you know how the drug affects you.
• Pregnancy: L Aprakast Injection is not recommended during pregnancy as it may harm the unborn baby. Use effective contraception during treatment and consult your doctor if you become pregnant.
Disclaimer
Sidmex Inovia strives to provide accurate and reliable information; however, all content on this website, including product descriptions and compositions, is for informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment.
Users are advised to consult a qualified healthcare professional before making any medical decisions. The information provided should not be used for self-diagnosis or self-medication.
All products listed are intended strictly for B2B and bulk inquiry purposes only. Sidmex Inovia does not promote direct consumer use and aims to support, not replace, the healthcare professional–patient relationship.
Product names, trademarks, and brands belong to their respective owners, and their use does not imply any affiliation or endorsement. Sidmex Inovia shall not be held responsible for any consequences arising from the use of the information provided on this website.